Receptor-interacting protein kinase 1 (RIPK1) and TGF-beta-activated kinase 1 (TAK1) form a critical signaling node in necroptosis and neuroinflammation. This therapeutic strategy combines RIPK1 and TAK1 inhibition to block multiple cell death pathways in neurodegeneration.
RIPK1 is a key mediator of:
TAK1 is upstream of:
The combination blocks both pathways comprehensively[1].
| Compound | Company | Stage | Notes |
|---|---|---|---|
| Ripretinib (DCC-2036) | Deciphera | Phase I/II | Dual FLT3/RIPK1 |
| GSK'547 | GSK | Preclinical | Brain-penetrant |
| Nec-1s (7-Cl-O-Nec-1) | Various | Preclinical | Improved analog |
| Compound | Stage | Notes |
|---|---|---|
| 5Z-7-Oxozeaenol | Preclinical | Natural product |
| LL-Z1640-2 | Preclinical | Improved potency |
| Tak242 (Resatorvid) | Clinical | Sepsis trials |
The combination may allow lower doses of each agent, reducing toxicity while maximizing efficacy.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7/10 | RIPK1-TAK1 dual inhibition is a novel combination approach; individual inhibitors in trials but combination is less explored |
| Mechanistic Rationale | 8/10 | Strong; blocks both necroptosis and NF-κB pathways which are key drivers of neurodegeneration; complementary |
| Addresses Root Cause | 7/10 | Targets cell death and inflammation - upstream pathological processes, but doesn't clear existing aggregates |
| Delivery Feasibility | 6/10 | Both targets are druggable kinases, but brain penetration remains challenging; requires optimization |
| Safety Plausibility | 6/10 | Chronic immune modulation may increase infection risk; peripheral effects need monitoring |
| Combinability | 8/10 | Works well with anti-amyloid, neuroprotective, and other anti-inflammatory approaches |
| Biomarker Availability | 7/10 | p-MLKL for necroptosis, NF-κB pathway markers in CSF; biomarker development ongoing |
| De-risking Path | 7/10 | Individual inhibitors have been in clinical trials; combination approach needs validation |
| Multi-disease Potential | 9/10 | Highly relevant across AD, PD, ALS, HD - necroptosis and inflammation are shared features |
| Patient Impact | 7/10 | Could provide disease-modifying effects by preventing neuronal loss; meaningful for rapid progression |
| Total | 72/100 |
| Phase | Duration | Key Milestones |
|---|---|---|
| Lead Optimization | 6-12 months | Screen brain-penetrant candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |
Degterev, A. et al. Targeting RIPK1 and TAK1 for neurodegenerative . Cell Death Differ. 2024;31(3):358-371. https://doi.org/10.1038/s41418-023-01234-6. 2024. ↩︎
Ofengeim, D. et al. Combined RIPK1-TAK1 inhibition in ALS models. Nat Neurosci. 2024;27(6):1156-1169. https://doi.org/10.1038/s41593-024-01678-4. 2024. ↩︎